The pathogenesis of Alzheimer's disease involves β amyloid (Aβ) accumulation known to
induce synaptic dysfunction and neurodegeneration. The brain's vulnerability to oxidative …

Novel agents addressing non-amyloid, non-tau targets in Alzheimer's Disease (AD)
comprise 70% of the AD drug development pipeline of agents currently in clinical trials. Most …

Overnutrition and modern diets containing high proportions of saturated fat are among the
major factors contributing to a low-grade state of inflammation, hyperglycemia and …

Statins are a class of widely prescribed drugs used to reduce low-density lipoprotein
cholesterol (LDL-C) and important to prevent cardiovascular diseases (CVD). Most statin …

We previously showed that simvastatin (SV) restored memory in a mouse model of
Alzheimer disease (AD) concomitantly with normalization in protein levels of memory-related …

Introduction Imbalanced cholesterol metabolism in the brain is one of the main
pathophysiological mechanisms involved in Alzheimer's disease. We investigated the effect …

The presence of insoluble aggregates of amyloid β (Aβ) in the form of neuritic plaques (NPs)
is one of the main features that define Alzheimer's disease. Studies have suggested that the …

Alzheimer's disease (AD) is a neurodegenerative brain disorder that has an increasingly
large burden on health and social care systems. The pathophysiology involves the …

Introduction Cholesterol homeostasis is critical for normal brain function. It is tightly
controlled by various biological elements. ATP-binding cassette transporter A1 (ABCA1) is a …

Type 2 diabetes mellitus and Alzheimer's disease (AD), both are chronic and progressive
diseases. Many cardiovascular and genetic risk factors are considered responsible for the …